Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease

• Main Authors: Yuting Ma (Author), Guangdong Zhang (Author), Zenggguang Kuang (Author), Qian Xu (Author), Tongtong Ye (Author), Xue Li (Author), Na Qu (Author), Fang Han (Author), Chengxia Kan (Author), Xiaodong Sun (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Empagliflozin (EMPA) therapy has led to improvements in patients with non-alcoholic fatty liver disease (NAFLD). Sestrin2 is a stress-inducible protein that controls the AMPK-mTOR pathway and inhibits oxidative damage in cells. This study investigated the functional implications of EMPA on the multi...